"Minerva Neurosciences recently reported its Q2 financial results, highlighting ongoing challenges with revenue generation and increased operational costs, which contribute to a cautious outlook. The overall sentiment remains negative, reflecting concerns about the company's ability to achieve significant milestones and attract institutional investment."